Hmm.... Howard said 90 days...? Seems a bit quick... I pulled this from the Company's initial disclosure which was submitted and reviewed by Howard...
So per the filings - it appears they need $2.8 million to complete construction and 'pilot' production facilities and get up to speed, then phase 2 with another $3.6 million... That's a lot to happen in 90 days...?!
(Per Company Initial Disclosure)
Corporate Funding and Direction
Phase One
Raise $2,800.000 million dollars, which will accomplish the following:
Use of Proceeds (Phase One)
1. Complete construction of R&D laboratory and Pilot production facilities.
2. Provide laboratory and pilot production equipment.
3. Scale up to pilot production capacity.
4. Register Facility and products with the FDA
5. Validate processes & equipment.
6. Do 90 day stabilities to get 2 year dating.
7. Write “Standard Operating Procedures”.
8. Expand laboratory area to be able to develop follow on products and line extensions.
9. Establish the manufacture, marketing, and sale of AQUAPRIN in limited quantities with
phase 1 funding. Thoroughly engage its professional marketing team to get AQUAPRIN
into distribution channels and in to drugstore shelves, hospitals, nursing homes, and into the
prescription drug markets and or make licensing and distribution agreements as soon as
possible.
10. Continue to develop advanced formulations, improvements and line extensions
11. Complete development of the Insta-Prin Emergency administration technology.
12. Develop several line extension of AQUAPRIN , such as: AQUAPRIN Cough & Cold,
AQUAPRIN Cold & Flu, AQUAPRIN Menstrual Pain. AQUAPRIN Migraine Pain.
13. Conduct clinical claim trials to make specific claims for the product.
Phase Two
Raise $3,600.000 million dollars, which will accomplish the following:
Use of Proceeds (Phase Two)
· Initiate full scale clinical studies in order to meet FDA and FTC requirements to make claims
of “fastest acting, Safest, and most effective” analgesic on the market.
• Make leasehold improvements to a physical plant.
• Establish full-scale production capability with phase 2 funding.
• Continue to develop advanced formulations, improvements and line extensions.
• Thoroughly engage its professional marketing team to get AQUAPRIN into retail
distribution channels and in to drugstore shelves, hospitals, nursing homes, and into the
prescription markets and or make licensing and distribution agreements as soon as possible.
• Complete development of the Insta-Prin emergency administration technology.
• Develop several line extension of AQUAPRIN, such as: AQUAPRIN Cough & Cold,
AQUAPRIN Cold & Flu, AQUAPRIN Menstrual Pain, AQUAPRIN Migraine Pain.
• License distribution for European and Asian markets.
AI
